Fulltext

N -methyl pyrrolidone (NMP) inhibits lipopolysaccharide-induced inflammation by suppressing NF-κB signaling

Ghayor, Chafik ; Gjoksi, Bebeka ; Siegenthaler, Barbara ; Weber, Franz

In: Inflammation Research, 2015, vol. 64, no. 7, p. 527-536

Add to personal list
    Title
    • N -methyl pyrrolidone (NMP) inhibits lipopolysaccharide-induced inflammation by suppressing NF-κB signaling
    Author
    • Ghayor, Chafik. Department of Cranio-Maxillofacial and Oral Surgery, Oral Biotechnology and Bioengineering, Center for Dental Medicine, Zentrum für Zahnmedizin, University Zürich, Plattenstrasse 11, 8032, Zürich, Switzerland
    • Gjoksi, Bebeka. Department of Cranio-Maxillofacial and Oral Surgery, Oral Biotechnology and Bioengineering, Center for Dental Medicine, Zentrum für Zahnmedizin, University Zürich, Plattenstrasse 11, 8032, Zürich, Switzerland
    • Siegenthaler, Barbara. Department of Cranio-Maxillofacial and Oral Surgery, Oral Biotechnology and Bioengineering, Center for Dental Medicine, Zentrum für Zahnmedizin, University Zürich, Plattenstrasse 11, 8032, Zürich, Switzerland
    • Weber, Franz. Department of Cranio-Maxillofacial and Oral Surgery, Oral Biotechnology and Bioengineering, Center for Dental Medicine, Zentrum für Zahnmedizin, University Zürich, Plattenstrasse 11, 8032, Zürich, Switzerland
    Document Type
    • Postprint
    OAI-PMH Identifier
    • oai:doc.rero.ch:332715
    Summary
    Objective: N-methyl pyrrolidone (NMP), a small bioactive molecule, stimulates bone formation and inhibits osteoclast differentiation and bone resorption. The present study was aimed to evaluate the anti-inflammatory potentials of NMP on the inflammatory process and the underlying molecular mechanisms in RAW264.7 macrophages. Materials and methods: RAW264.7 macrophages and mouse primary bone marrow macrophages (mBMMs) were used as an in vitro model to investigate inflammatory processes. Cells were pre-treated with or without NMP and then stimulated with lipopolysaccharides (LPS). The productions of cytokines and NO were determined by proteome profiler method and nitrite analysis, respectively. The expressions of nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) were measured by Western blotting and/or qPCR. Western blot, ELISA-base reporter assay, and immunofluorescence were used to evaluate the activation of MAP kinases and NF-κB. Results: LPS-induced mRNA expressions of TNF-α, IL-1β, IL-6, iNOS, and COX-2 were inhibited by NMP in a dose-dependent manner. NMP also suppressed the LPS-increased productions of iNOS and NO. The proteome profiler array showed that several cytokines and chemokines involved in inflammation and up-regulated by LPS stimulation were significantly down-regulated by NMP. Additionally, this study shows that the effect of NMP is mediated through down-regulation of NFκB pathway. Conclusions: Our results show that NMP inhibits the inflammatory mediators in macrophages by an NFκB-dependent mechanism, based on the epigenetical activity of NMP as bromodomain inhibitor. In the light of its action on osteoblast and osteoclast differentiation process and its anti-inflammatory potential, NMP might be used in inflammation-related bone loss.